RTA certifies share demat compliance for Sep 2026 quarter

Compliance View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.0%Reaction day

₹318.00

prior close

₹314.00

announcement price

In-mkt

timing

Nifty Microcap 250market+0.2%-0.2% vs market

Pharmaceuticals peers, median of 168sector-0.3%+0.3% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.2

15m

+0.1

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.0+0.2-0.2-0.3+0.3

Next day

-1.5+0.9-2.4-0.3-1.2

-3.4-0.8-2.7-1.2-2.3

-2.3-0.1-2.2-1.0-1.3

-4.7-1.7-3.0-2.6-2.2

-6.1-4.3-1.8-3.8-2.3

-9.8-7.5-2.3-6.4-3.4

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 168Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma filed a Regulation 74(5) certificate for the quarter and half year ended September 30, 2026. Bigshare Services, the company's Registrar and Transfer Agent, issued the certificate. It confirms shares received for dematerialisation were processed and accepted or rejected by depositories. Physical certificates were mutilated and cancelled after verification. Depository names were substituted as registered owners in the members register within 15 days. This is a routine procedural compliance filing with no operational impact.

Likely market impact

Routine procedural compliance. No material impact on shareholders or stock price.